SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors focus on the company's aggressive preparation for its August FDA decision, highlighted by the strategic appointment of a new Chief Commercial Officer with extensive Duchenne muscular dystrophy experience. The community is actively discussing the high-stakes legal dispute with Nippon Shinyaku, with many stakeholders banking on the company's ability to maintain its independence and launch Deramiocel successfully regardless of the litigation's outcome.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as the market reacts to the unveiling of new high-end AR glasses, sparking intense community debate over their premium price point and the company's long-term hardware strategy. While some users emphasize the potential of Snap's patent portfolio and AI integration, many are voicing skepticism regarding the device's mass-market viability and the company's leadership direction.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is capturing market attention as institutional interest in advanced nuclear energy intensifies, with investors closely watching potential multi-billion dollar investment pledges from international partners. The community remains divided between those betting on the company's long-term commercialization of small modular reactors to power AI data centers and those skeptical of its timeline and reliance on speculative funding.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently driving significant community engagement due to its role as a critical bottleneck-solution in the AI infrastructure and silicon photonics supply chain. Traders are actively debating the stock's high valuation multiples against its strong backlog and potential for follow-on orders from major hyperscalers, often drawing comparisons to other high-growth semiconductor picks.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending due to a sharp decline in price following insider stock sales, fueling intense debate between retail bulls who emphasize its strong revenue growth and enterprise adoption and bearish traders who cite high valuation, stock-based compensation, and competition from AI tools. The community is focused on whether this drawdown represents a final shakeout before a potential short squeeze or evidence that software valuations are correcting alongside the IPO lock-up expiration.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is seeing intense trading activity driven by the announcement of a Navy-linked missile development contract, which has intensified the ongoing battle between retail investors targeting a short squeeze and concerns regarding potential dilution. The community is heavily focused on the company's pivot into integrated defense manufacturing, with debates centering on whether this recent contract win will deliver sustainable revenue growth or if price volatility will continue to favor short-term traders.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2024 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is trending as traders closely monitor developments regarding potential acquisition interest, with the company currently positioned as a key topic in media sector M&A conversations. Community discussion is focused on analyzing the feasibility of rumored takeover interest while evaluating the stock's recent price volatility and the impact of the streaming landscape on its valuation.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is facing significant downward pressure as the FDA issued a Complete Response Letter rejecting the approval of its lead drug, troriluzole, for spinocerebellar ataxia. The community is actively debating the impact of this regulatory setback on the company's long-term pipeline, while management shifts its focus to key clinical programs including obesity and epilepsy treatments.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending due to volatile price action following a strong quarterly earnings report that featured the company's first revenue growth in nearly five years. Investors are actively debating whether this is a genuine long-term turnaround fueled by recent acquisitions or a recurring pump-and-dump scheme driven by management's history of dilution.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is facing intense volatility as the community remains sharply divided ahead of upcoming clinical milestones, with active discussions focused on the potential impact of the Phase 1 and Phase 2 data readouts for its lead candidate, ABCL635. Investors are intensely debating the stock's long-term value and the credibility of bullish sentiment versus persistent short-seller pressure, while technical traders closely monitor institutional accumulation and recent analyst coverage.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$GRPN  
Trying to show how tight the share float can be coiled with these buybacks. From Jan 1 to May 7 (Q1 earnings), 2 804 479 shares were bought back. Averaging this out over the trading days that have passed over that time gives us an average of 32 235 shares bought and retired.  
 
The bottom portion shows the average rate of shares retired daily and effect on the SF at important times. Once we reach Q2 earnings, approx 4.8 mil shares retired. This leaves the public float remaining at 17 mil shares. Against the current short float of 12.5 mil shares, this puts the effective SI% at 73%.  
 
There are 17.7 million locked holders (activist investors/funds, employees with RSUs). When we subtract these from the effective remaining float, well, as you can see, things don&#39;t look too good.. 
 
Note that OI numbers are based off of OTM call options from aug 21 onwards. I personally don&#39;t expect a pop until at least the week of Aug 5 (est. Q2 earnings), and kept my calcs conservative in mind of that.

Colton Hinderaker

Patrick McHugh

JeDon Tomlin

Pikersville

J Mob

StockTwits for iOS

StockTwits Web

Groupon Inc

  
Trying to show how tight the share float can be coiled with these buybacks. From Jan 1 to May 7 (Q1 earnings), 2 804 479 shares were bought back. Averaging this out over the trading days that have passed over that time gives us an average of 32 235 shares bought and retired.  
 
The bottom portion shows the average rate of shares retired daily and effect on the SF at important times. Once we reach Q2 earnings, approx 4.8 mil shares retired. This leaves the public float remaining at 17 mil shares. Against the current short float of 12.5 mil shares, this puts the effective SI% at 73%.  
 
There are 17.7 million locked holders (activist investors/funds, employees with RSUs). When we subtract these from the effective remaining float, well, as you can see, things don't look too good.. 
 
Note that OI numbers are based off of OTM call options from aug 21 onwards. I personally don't expect a pop until at least the week of Aug 5 (est. Q2 earnings), and kept my calcs conservative in mind of that.